Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease

Avin, Keith G.; Chen, Neal X.; Organ, Jason M.; Zarse, Chad A.; O’Neill, Kalisha D.; Conway, Richard G.; Konrad, Robert J.; Bacallao, Robert L.; Allen, Matthew R.; Moe, Sharon M.

doi:10.1371/journal.pone.0159411

Cited by 73 publications

(78 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Likely mechanisms that mediate this relationship include impaired skeletal muscle regeneration induced by oxidative stress, increased serum myostatin, negative balance of protein homeostasis, and hypogonadism found in patients with CKD. [37][38][39] Additionally, patients with AKI demonstrate increased serum markers for sarcopenia, supporting our findings. 40 Our study found that sarcopenic patients had significantly higher incidence and odds of developing pneumonia and requiring transfusion of blood products.…”

Section: Discussionsupporting

confidence: 88%

Comparative Analysis on the Effects of Sarcopenia following Primary Total Knee Arthroplasty: A Retrospective Matched-Control Analysis

et al. 2020

View full text Add to dashboard Cite

AbstractDespite the high incidence of sarcopenia in the orthopaedic community, studies evaluating the influence of sarcopenia following primary total knee arthroplasty (TKA) are limited. Therefore, the purpose of this study is to determine if sarcopenic patients undergoing primary TKA have higher rates of (1) in-hospital lengths of stay (LOS); (2) medical complications; (3) implant-related complications; (4) fall risk; (5) lower extremity fracture risk; and (6) costs of care. Sarcopenia patients were matched to controls in a 1:5 ratio according to age, sex, and medical comorbidities. The query yielded 90,438 patients with (n = 15,073) and without (n = 75,365) sarcopenia undergoing primary TKA. Primary outcomes analyzed included: in-hospital LOS, 90-day medical complications, 2-year implant-related complications, fall risk, lower extremity fracture risk, and costs of care. A p-value of less than 0.05 was considered statistically significant. Patients with sarcopenia undergoing primary TKA had greater in-hospital LOS (4 vs. 3 days, p < 0.0001). Sarcopenic patients were also found to have increased incidence and odds of 90-day medical complications (2.9 vs. 1.1%; odds ratio [OR] = 2.83, p < 0.0001), falls (0.9 vs. 0.3%; OR = 3.54, p < 0.0001), lower extremity fractures (1.0 vs. 0.2%; OR = 5.54, p < 0.0001), and reoperation (0.9 vs. 0.5%; OR = 1.87, p < 0.0001). Additionally, sarcopenic patients had greater 2-year implant-related complications (4.3 vs. 2.4%; OR = 1.80, p < 0.0001), as well as day of surgery ($52,900 vs. 48,248, p < 0.0001), and 90-day ($68,303 vs. $57,671, p < 0.0001) costs compared with controls. This analysis of over 90,000 patients demonstrates that patients with sarcopenia undergoing primary TKA have greater in-hospital LOS, increased odds of 90-day medical complications, falls, lower extremity fractures, and reoperations. Additionally, sarcopenia was associated with greater 2-year implant-related complications, day of surgery costs, and 90-day costs. The study is useful as it can allow orthopaedic surgeons to properly educate these patients of the potential complications which may occur following their surgery.

show abstract

Section: Discussionsupporting

confidence: 88%

Comparative Analysis on the Effects of Sarcopenia following Primary Total Knee Arthroplasty: A Retrospective Matched-Control Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…‘Normal’ aging has been shown to impair skeletal muscle ‘regeneration’, which is the formation of new myofibers from dormant satellite cells in skeletal muscle [31]. CKD is also associated with impaired regeneration (reduced cell activation and expression of myogenic regulatory factors) [32]. Muscle regeneration and size have been shown to be effected by myostatin, a negative regulator of skeletal muscle mass.…”

Section: Pathophysiology Of Sarcopenia In Chronic Kidney Diseasementioning

confidence: 99%

Clinical relevance of sarcopenia in chronic kidney disease

Moorthi

Avin

2017

Current Opinion in Nephrology and Hypertension

Self Cite

196

142

View full text Add to dashboard Cite

Purpose of review In this article, we review sarcopenia in chronic kidney disease (CKD). We aim to present how definitions of sarcopenia from the general population may pertain to those with CKD, its assessment by clinicians and emerging therapies for sarcopenia in CKD. For this review, we limit our description and recommendations to patients with CKD who are not on dialysis. Recent findings Poorer parameters of lean mass, strength and physical function are associated with worsening patient-centered outcomes such as limiting mobility, falls and mortality in CKD; however, the magnitude of these associations are different in those with and without CKD. Sarcopenia in CKD is a balance between skeletal muscle regeneration and catabolism, which are both altered in the uremic environment. Multiple pathways are involved in these derangements, which are briefly reviewed. Differences between commonly used terms cachexia, frailty, protein-energy wasting, dynapenia and sarcopenia are described. Therapeutic options in predialysis CKD are not well studied; therefore, we review exercise options and emerging pharmacological therapies. Summary Sarcopenia, now with its own International Classification of Diseases, 10th Revision (ICD-10) code, is of importance clinically and should be accounted for in research studies in patients with CKD. Multiple therapies for sarcopenia are in development and will hopefully be available for our patients in the future.

show abstract

“…Pro-myostatin is not affected by menstrual cycle (35) and females have slightly lower levels compared to males (25). High plasma levels of myostatin were found in in rats with chronic kidney disease (CKD) (36) and in patients with chronic obstructive pulmonary disease (COPD) (37).…”

Section: Pre-analytical Factorsmentioning

confidence: 99%

Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output

Lombardi¹,

Sansoni²,

Banfi³

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Abstract:In the last few years, a growing number of molecules have been associated to an endocrine function of the skeletal muscle. Circulating myokine levels, in turn, have been associated with several pathophysiological conditions including the cardiovascular ones. However, data from different studies are often not completely comparable or even discordant. This would be due, at least in part, to the whole set of situations related to the preparation of the patient prior to blood sampling, blood sampling procedure, processing and/or store. This entire process constitutes the pre-analytical phase. The importance of the preanalytical phase is often not considered. However, in routine diagnostics, the 70% of the errors are in this phase. Moreover, errors during the pre-analytical phase are carried over in the analytical phase and affects the final output. In research, for example, when samples are collected over a long time and by different laboratories, a standardized procedure for sample collecting and the correct procedure for sample storage are acknowledged. In this review, we discuss the pre-analytical variables potentially affecting the measurement of myokines with cardiovascular functions.

show abstract

Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease

Cited by 73 publications

References 47 publications

Comparative Analysis on the Effects of Sarcopenia following Primary Total Knee Arthroplasty: A Retrospective Matched-Control Analysis

Comparative Analysis on the Effects of Sarcopenia following Primary Total Knee Arthroplasty: A Retrospective Matched-Control Analysis

Clinical relevance of sarcopenia in chronic kidney disease

Measuring myokines with cardiovascular functions: pre-analytical variables affecting the analytical output

Contact Info

Product

Resources

About